Donald Ogilvie

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes et al. · PubMed · 2002 · 802 citations

Medicine, Medicinal Chemistry, Pharmacology +15

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 711 citations · Full text

Medicine, Oncology, Pharmacology +17

A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones

J. Riley, Rachel Butler, Donald Ogilvie et al. · Nucleic Acids Research · 1990 · 646 citations · Full text

Life Sciences, Biotechnology, Genetics +12

The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells

William J. Harris, Xu Huang, James T. Lynch et al. · Cancer Cell · 2012 · 555 citations

Medicine, Molecular Biology, Oncology +16

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley et al. · Molecular Cancer Therapeutics · 2012 · 461 citations · Full text

Medicine, Oncology, Pharmacology +16